← All trials
NCT04952129
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2021
- Primary completion
- Feb 1, 2022
- Completion date
- Jul 1, 2022
- First posted
- Jul 7, 2021
- Last posted
- Jul 14, 2021
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of AucklandLead sponsor
- University of AucklandReponsible party - principal investigator
- University of AucklandOverall official - principal investigator
- Waikato HospitalCollaborator
- Cancer Trials New ZealandCollaborator
- Counties Manukau HealthCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.